Added to YB: 2024-07-25
Pitch date: 2024-07-23
MREO [bullish]
Mereo BioPharma Group plc
-47.46%
current return
Author Info
Raging Bull Investments is a lawyer by background who shares actionable investment ideas on value opportunities with a catalyst. Sign up for the newsletter.
Company Info
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
Market Cap
$281.6M
Pitch Price
$4.13
Price Target
7.80 (+259%)
Dividend
N/A
EV/EBITDA
-5.22
P/E
-5.60
EV/Sales
452.15
Sector
Biotechnology
Category
growth
Mereo BioPharma Group plc - $MREO
MREO: Late-stage biotech w/ 2 promising assets. Setrusumab for OI shows strong P2 data (67% AFR reduction, 22% BMD increase). Alvelestat for AATD w/ P3 starting 2024. $600M mkt cap, $510M EV. Setrusumab worth >$6/sh. Imminent alvelestat deal. 50-100%+ upside potential in 6-8mo. Risks: clinical trial failure, deal falls through.
Read full article (20 min)